Loading clinical trials...
Loading clinical trials...
This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT07665931 · Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Hyperinflation
NCT07646587 · COPD (Chronic Obstructive Pulmonary Disease)
NCT07635446 · COPD
NCT07245576 · Asthma, COPD
NCT06847061 · Chronic Obstructive Pulmonary Disease (COPD
Novartis Investigative Site
Frankfurt
Novartis Investigative Site
Großhansdorf
Novartis Investigative Site
Hamburg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions